Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 33 of 114

  1. D702NC00001

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  2. D7310C00001

    AstraZeneca AB

    Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

    phase 3 small molecule active

    1 trial

  3. D7402C00001

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  4. D7632C00001

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  5. D781PC00001

    AstraZeneca AB

    Advanced HER2-expressing Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  6. D7984C00002

    AstraZeneca AB

    Locally advanced cervical cancer

    phase 3 small molecule active

    1 trial

  7. D7988C00001

    AstraZeneca AB

    Unresectable Pleural Mesothelioma

    phase 3 small molecule active

    1 trial

  8. D798AC00001

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  9. D8220C00027

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  10. D8227C00001

    Lacuna Pharma Pty Ltd

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  11. D8311C00001

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  12. D8532C00001

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  13. D8534C00001

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  14. D8535C00001

    AstraZeneca AB

    ER+/HER2- Early Breast Cancer

    phase 3 small molecule active

    1 trial

  15. D8610C00001

    AstraZeneca AB

    Respiratory Syncytial Virus and Human Metapneumovirus

    phase 3 small molecule active

    1 trial

  16. D8991C00001

    AstraZeneca AB

    Advanced Platinum-resistant Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  17. D9075C00001

    AstraZeneca AB

    The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.

    phase 3 small molecule active

    1 trial

  18. D9078C00001

    AstraZeneca AB

    Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  19. D9103C00001

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  20. D9106C00001

    AstraZeneca AB

    Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).

    phase 3 small molecule active

    1 trial

  21. D910DC00001

    AstraZeneca AB

    Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)

    phase 3 small molecule active

    1 trial

  22. D910GC00001

    AstraZeneca AB

    Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).

    phase 3 small molecule active

    1 trial

  23. D910PC00001 - Volga

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  24. D910SC00001/KUNLUN

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  25. D910VC00001

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  26. D9180C00003

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  27. D9180C00004

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  28. D9180C00012

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  29. D9180C00015

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 other active

    1 trial

  30. D9268C00001

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  31. D926PC00001

    AstraZeneca AB

    Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  32. D926QC00001

    AstraZeneca AB

    Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  33. D926TC00001

    AstraZeneca AB

    Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature

    phase 3 small molecule active

    1 trial

  34. D9311C00001

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  35. D933AC00001

    AstraZeneca AB

    First-line patients with advanced biliary tract cancers (BTC)

    phase 3 small molecule active

    1 trial

  36. D933QC00001

    AstraZeneca AB

    Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)

    phase 3 small molecule active

    1 trial

  37. D933SC00001

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  38. D9481C00001

    AstraZeneca AB

    Hyperkalaemia

    phase 3 small molecule active

    1 trial

  39. D9604C00001

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  40. D9612C09998

    AstraZeneca AB

    Erosive Esophagitis

    phase 3 small molecule active

    1 trial

  41. D9670C00001

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

  42. D967RC00001

    AstraZeneca AB

    Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)

    phase 3 small molecule active

    1 trial

  43. D967SC00001

    AstraZeneca AB

    Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations

    phase 3 small molecule active

    1 trial

  44. D967UC00001

    AstraZeneca AB

    HER2-positive metastatic breast cancer

    phase 3 small molecule active

    1 trial

  45. D9722C00001

    AstraZeneca AB

    Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  46. D9723C00001

    AstraZeneca AB

    Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  47. D9727C00001

    AstraZeneca AB

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  48. D9802C00001

    AstraZeneca AB

    Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.